{
    "id": 327,
    "fullName": "EGFR act mut",
    "impact": "unknown",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "EGFR act mut indicates that this variant results in a gain of function in the Egfr protein. However, the specific amino acid change has not been identified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "act mut",
    "createDate": "03/13/2014",
    "updateDate": "09/21/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1702,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapitinib (AZD8931) inhibited EGFR, ERBB2, and ERBB3 kinase activity, and inhibited growth in several non-small cell lung cancer cell lines and xenograft models, including those with EGFR activating mutations (PMID: 20145185).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 910,
                "therapyName": "Sapitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 42,
                    "pubMedId": 20145185,
                    "title": "AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20145185"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5291,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Glesatinib (MGCD265) and Tarceva (erlotinib) combination treatment resulted in partial response in a non-small cell lung carcinoma patient harboring an EGFR activating mutation (J Clin Oncol 30, 2012 (suppl; abstr e13602)).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 1126,
                "therapyName": "Erlotinib + Glesatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4988,
                    "pubMedId": null,
                    "title": "MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR, in combination with erlotinib in patients with advanced solid tumors.",
                    "url": "http://meetinglibrary.asco.org/content/96526-114"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2563,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Nerlynx (neratinib) demonstrated limited clinical activity in EGFR-mutant non-small cell lung cancer patients with prior EGFR TKI therapy, with a response rate of 3.4% (3/88), stable disease as best response in 50% (44/88), and prolonged stable disease in 10%, (9/88) (PMID: 20479403).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3315,
                    "pubMedId": 20479403,
                    "title": "Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20479403"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6719,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ABT-806 treatment in patients with advanced solid tumors that often express EGFR amplification or EGFR vIII was well-tolerated, demonstrated safety, and resulted in stable disease in two patients (PMID: 25895099).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 4256,
                "therapyName": "ABT-806",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5781,
                    "pubMedId": 25895099,
                    "title": "A phase 1 study of ABT-806 in subjects with advanced solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25895099"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12966,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Alecensa (alectinib) is not indicated for use in non-small cell lung cancer patients with sensitizing EGFR mutations (including exon 19 deletions and L858R) who relapsed on EGFR tyrosine kinase inhibitor therapy (NCCN.org).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17399,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Iressa (gefitinib) is included in guidelines as first-line therapy for patients with metastatic non-small cell lung cancer harboring sensitizing EGFR activating mutations (PMID: 30715168, PMID: 30285222; ESMO.org).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15431,
                    "pubMedId": 30715168,
                    "title": "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30715168"
                },
                {
                    "id": 15432,
                    "pubMedId": 30285222,
                    "title": "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30285222"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1873,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III clinical trial, Iressa (gefitinib) treatment resulted in an objective response rate of 71.2% (94/132) and increased progression-free survival in non-small cell lung cancer patients harboring EGFR activating mutations (PMID: 19692680).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2375,
                    "pubMedId": 19692680,
                    "title": "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19692680"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6043,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vizimpro (dacomitinib) and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFRvIII in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 4009,
                "therapyName": "BMS-754807 + Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17842,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, immunotherapies including Tecentriq (atezolizumab) (n=5), Opdivo (nivolumab) (n=17), Keytruda (pembrolizumab) (n=36), and Camrelizumab (SHR-1210) (n=20) resulted in significantly shorter median progression-free survival (51.0 vs 70.5 days, HR=2.47, p=0.0037) in non-small cell lung cancer patients harboring EGFR (n=7) or ERBB2 (HER2) (n=7) activating mutations compared to wild-type patients (PMID: 31085721).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15767,
                    "pubMedId": 31085721,
                    "title": "Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31085721"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17402,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tagrisso (osimertinib) is included in guidelines for patients with metastatic non-small cell lung cancer harboring sensitizing EGFR activating mutations (PMID: 30715168, PMID: 30285222; ESMO.org).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15431,
                    "pubMedId": 30715168,
                    "title": "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30715168"
                },
                {
                    "id": 15432,
                    "pubMedId": 30285222,
                    "title": "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30285222"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17401,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vizimpro (dacomitinib) is included in guidelines as first-line therapy for patients with metastatic non-small cell lung cancer harboring sensitizing EGFR activating mutations (PMID: 30715168, PMID: 30285222; ESMO.org).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 714,
                "therapyName": "Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15431,
                    "pubMedId": 30715168,
                    "title": "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30715168"
                },
                {
                    "id": 15432,
                    "pubMedId": 30285222,
                    "title": "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30285222"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3262,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II clinical trial, the combination of Luminespib (AUY922) and Tarceva (erlotinib) demonstrated limited clinical benefit in patients with EGFR-mutant non-small cell carcinoma with acquired resistance to EGFR tyrosine kinase inhibitors, with 16% (4/25) patients achieving partial response (PMID: 25870087).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 2799,
                "therapyName": "Erlotinib + Luminespib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3702,
                    "pubMedId": 25870087,
                    "title": "Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870087"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16843,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, WSD0922 treatment prolonged survival in cell line xenograft models of intracranial metastasis of non-small cell lung cancer harboring EGFR activating mutations (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1326).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 8206,
                "therapyName": "WSD0922",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14952,
                    "pubMedId": null,
                    "title": "WSD0922: A BBB penetrable EGFR/EGFRVIII inhibitor for the treatment of GBM and metastatic CNS tumor",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17841,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, immunotherapies including Tecentriq (atezolizumab) (n=5), Opdivo (nivolumab) (n=17), Keytruda (pembrolizumab) (n=36), and Camrelizumab (SHR-1210) (n=20) resulted in significantly shorter median progression-free survival (51.0 vs 70.5 days, HR=2.47, p=0.0037) in non-small cell lung cancer patients harboring EGFR (n=7) or ERBB2 (HER2) (n=7) activating mutations compared to wild-type patients (PMID: 31085721).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15767,
                    "pubMedId": 31085721,
                    "title": "Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31085721"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17439,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tarceva (erlotinib) in combination with (bevacizumab) is included in guidelines as first-line therapy for patients with metastatic non-small cell lung cancer harboring sensitizing EGFR activating mutations (PMID: 30715168, PMID: 30285222; ESMO.org).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 1146,
                "therapyName": "Bevacizumab + Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15431,
                    "pubMedId": 30715168,
                    "title": "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30715168"
                },
                {
                    "id": 15432,
                    "pubMedId": 30285222,
                    "title": "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30285222"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17400,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tarceva (erlotinib) is included in guidelines as first-line therapy for patients with metastatic non-small cell lung cancer harboring sensitizing EGFR activating mutations (PMID: 30715168, PMID: 30285222; ESMO.org).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15431,
                    "pubMedId": 30715168,
                    "title": "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30715168"
                },
                {
                    "id": 15432,
                    "pubMedId": 30285222,
                    "title": "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30285222"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16845,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, WSD0922 treatment resulted in tumor regression in patient-derived xenograft (PDX) models of cetuximab-resistant head and neck squamous cell carcinoma harboring EGFR activating mutations (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1326).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 8206,
                "therapyName": "WSD0922",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14952,
                    "pubMedId": null,
                    "title": "WSD0922: A BBB penetrable EGFR/EGFRVIII inhibitor for the treatment of GBM and metastatic CNS tumor",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12980,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Alunbrig (brigatinib) is not indicated for use in non-small cell lung cancer patients with sensitizing EGFR mutations (including exon 19 deletions and L858R) who relapsed on EGFR tyrosine kinase inhibitor therapy (NCCN.org).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17403,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Gilotrif (afatinib) is included in guidelines as first-line therapy for patients with metastatic non-small cell lung cancer harboring sensitizing EGFR activating mutations (PMID: 30715168, PMID: 30285222; ESMO.org).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15431,
                    "pubMedId": 30715168,
                    "title": "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30715168"
                },
                {
                    "id": 15432,
                    "pubMedId": 30285222,
                    "title": "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30285222"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6042,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFRvIII in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 4008,
                "therapyName": "Gefitinib + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1310,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II study, XL647 demonstrated antitumor activity and increased progression-free survival in non-small cell lung cancer patients harboring EGFR activating mutations (PMID: 22722787).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 967,
                "therapyName": "XL647",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1015,
                    "pubMedId": 22722787,
                    "title": "Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22722787"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17840,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, immunotherapies including Tecentriq (atezolizumab) (n=5), Opdivo (nivolumab) (n=17), Keytruda (pembrolizumab) (n=36), and Camrelizumab (SHR-1210) (n=20) resulted in significantly shorter median progression-free survival (51.0 vs 70.5 days, HR=2.47, p=0.0037) in non-small cell lung cancer patients harboring EGFR (n=7) or ERBB2 (HER2) (n=7) activating mutations compared to wild-type patients (PMID: 31085721).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 1201,
                "therapyName": "Atezolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15767,
                    "pubMedId": 31085721,
                    "title": "Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31085721"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17499,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MTI-31 inhibited proliferation and migration of non-small cell lung cancer cell lines harboring oncogenic EGFR mutations in culture, and inhibited tumor growth in xenograft models (PMID: 30796032).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 8516,
                "therapyName": "MTI-31",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15515,
                    "pubMedId": 30796032,
                    "title": "A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial-Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30796032"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16842,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, WSD0922 treatment resulted in dose-dependent inhibition of EGFRvIII phosphorylation and downstream signaling in patient-derived xenograft (PDX) models of glioblastoma multiforme, and growth inhibition in ex-vivo PDX (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1326).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 8206,
                "therapyName": "WSD0922",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14952,
                    "pubMedId": null,
                    "title": "WSD0922: A BBB penetrable EGFR/EGFRVIII inhibitor for the treatment of GBM and metastatic CNS tumor",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16844,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, WSD0922 treatment resulted in tumor regression in patient-derived xenograft (PDX) models of squamous lung cancer harboring EGFR activating mutations (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1326).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 8206,
                "therapyName": "WSD0922",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14952,
                    "pubMedId": null,
                    "title": "WSD0922: A BBB penetrable EGFR/EGFRVIII inhibitor for the treatment of GBM and metastatic CNS tumor",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3298,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, non-small cell lung cancer patients harboring EGFR activating mutations treated with Tarceva (erlotinib), in combination with MK-2206, demonstrated a 9% (4/45) response rate, which did not reach the primary endpoint rate of 20% or more, therefore, indicating no benefit (PMID: 26106072).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 1097,
                "therapyName": "Erlotinib + MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3719,
                    "pubMedId": 26106072,
                    "title": "Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26106072"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 86,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rociletinib (CO-1686) inhibited tumor growth in xenograft models of human non-small cell lung cancer cell lines harboring EGFR activating mutations (PMID: 24065731).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 157,
                    "pubMedId": 24065731,
                    "title": "Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24065731"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5912,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AP32788 inhibited growth of transformed cell lines over expressing EGFR activating mutations in culture, regardless of the presence or absence of EGFR T790M (AACR, Cancer Res: April 2016; Volume 57, Abstract #2644).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 3981,
                "therapyName": "AP32788",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5195,
                    "pubMedId": null,
                    "title": "AP32788, a potent, selective inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, in preclinical models",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=407e597a-33c8-4936-87f4-08ee4b23e8b9&cKey=34ee7ebf-07c6-40ea-825f-28fb5018ec92&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9781,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cell lines harboring activating EGFR mutations demonstrated sensitivity to the combination of amlexanox and Selumetinib (AZD6244), resulting in synergistic growth inhibition in culture and reduced tumor growth in xenograft models (PMID: 27287717).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 5229,
                "therapyName": "Amlexanox + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7601,
                    "pubMedId": 27287717,
                    "title": "IKBKE Is a Substrate of EGFR and a Therapeutic Target in Non-Small Cell Lung Cancer with Activating Mutations of EGFR.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27287717"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2425,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Naquotinib (ASP8273) demonstrated preliminary antitumor activity in non-small cell lung patients harboring EGFR activating mutations (J Clin Oncol 33, 2015 (suppl; abstr 8014).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 1082,
                "therapyName": "Naquotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3048,
                    "pubMedId": null,
                    "title": "ASP8273, a mutant-selective irreversible EGFR inhibitor in patients (pts) with NSCLC harboring EGFR activating mutations: Preliminary results of first-in-human phase I study in Japan.",
                    "url": "http://meetinglibrary.asco.org/content/147772-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18271,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Naquotinib (ASP8273) treatment did not result in improved efficacy compared to Tarceva (erlotinib)/Iressa (gefitinib) in patients with non-small cell lung cancer harboring an EGFR activating mutation, demonstrating a median progression-free survival of 9.3 mo vs 9.6 mo, an overall response rate of 33% (166/267) vs 47.9% (126/263), a disease control rate of 62.2% (166/267) vs 66.2% (174/263), and a duration of response of 9.17 mo vs 9.03 mo, respectively (PMID: 31070709; NCT02588261).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 1082,
                "therapyName": "Naquotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16081,
                    "pubMedId": 31070709,
                    "title": "A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31070709"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17843,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, immunotherapies including Tecentriq (atezolizumab) (n=5), Opdivo (nivolumab) (n=17), Keytruda (pembrolizumab) (n=36), and Camrelizumab (SHR-1210) (n=20) resulted in significantly shorter median progression-free survival (51.0 vs 70.5 days, HR=2.47, p=0.0037) in non-small cell lung cancer patients harboring EGFR (n=7) or ERBB2 (HER2) (n=7) activating mutations compared to wild-type patients (PMID: 31085721).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 6137,
                "therapyName": "Camrelizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15767,
                    "pubMedId": 31085721,
                    "title": "Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31085721"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17437,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Iressa (gefitinib) in combination with Paraplatin (carboplatin) and Alimta (pemetrexed) is included in guidelines at a first-line option for patients with metastatic non-small cell lung cancer harboring sensitizing EGFR activating mutations (PMID: 30715168, PMID: 30285222; ESMO.org).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 8501,
                "therapyName": "Carboplatin + Gefitinib + Pemetrexed",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15431,
                    "pubMedId": 30715168,
                    "title": "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30715168"
                },
                {
                    "id": 15432,
                    "pubMedId": 30285222,
                    "title": "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30285222"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20223,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, addition of Paraplatin (carboplatin) and Alimta (pemetrexed) to Iressa (gefitinib) improved progression-free survival (16 vs 8 mo, HR=0.51, p<0.001) and overall survival (not reached vs 17 mo, HR=0.45, p<0.001) in patients with metastatic non-small cell lung cancer harboring EGFR activating mutations, including EGFR exon 19 deletion, L858R, L861Q, and G719X, but also resulted in higher incidence of clinically relevant toxicity (51% vs 25%, p<0.001) (PMID: 31411950).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 8501,
                "therapyName": "Carboplatin + Gefitinib + Pemetrexed",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17741,
                    "pubMedId": 31411950,
                    "title": "Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31411950"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12976,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Zykadia (ceritinib) is not indicated for use in non-small cell lung cancer patients with sensitizing EGFR mutations (including exon 19 deletions and L858R) who relapsed on EGFR tyrosine kinase inhibitor therapy (NCCN.org).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1775,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-701 and Iressa (gefitinib) combination treatment inhibited growth of non-small cell lung cancer cell lines harboring EGFR activating mutations and over expressing HGF in culture and in cell line xenograft models which were resistant to Iressa (gefitinib) as monotherapy (PMID: 20716641).",
            "molecularProfile": {
                "id": 3199,
                "profileName": "EGFR act mut HGF over exp"
            },
            "therapy": {
                "id": 2179,
                "therapyName": "Gefitinib + TAK-701",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2036,
                    "pubMedId": 20716641,
                    "title": "TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20716641"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3263,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II clinical trial, the combination of Luminespib (AUY922) and Tarceva (erlotinib) demonstrated limited clinical benefit in patients with EGFR-mutant non-small cell carcinoma with acquired resistance to EGFR tyrosine kinase inhibitors, including patients with EGFR T790M, with 16% (4/25) patients achieving partial response (PMID: 25870087).",
            "molecularProfile": {
                "id": 13014,
                "profileName": "EGFR T790M EGFR act mut"
            },
            "therapy": {
                "id": 2799,
                "therapyName": "Erlotinib + Luminespib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3702,
                    "pubMedId": 25870087,
                    "title": "Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870087"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17503,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MTI-31 inhibited proliferation and migration and increased PD-L1 degradation in a non-small cell lung cancer cell line harboring an oncogenic EGFR mutation and secondary EGFR T790M mutation in culture, and inhibited tumor growth in xenograft models (PMID: 30796032).",
            "molecularProfile": {
                "id": 13014,
                "profileName": "EGFR T790M EGFR act mut"
            },
            "therapy": {
                "id": 8516,
                "therapyName": "MTI-31",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15515,
                    "pubMedId": 30796032,
                    "title": "A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial-Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30796032"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12671,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with ASP8273 resulted in a partial response in 41% (19/46) of non-small cell lung carcinoma patients co-harboring EGFR T790M and an EGFR activating mutation, demonstrating almost undetectable levels of the mutations in cell-free DNA (PMID: 28954786; NCT02113813).",
            "molecularProfile": {
                "id": 13014,
                "profileName": "EGFR T790M EGFR act mut"
            },
            "therapy": {
                "id": 1082,
                "therapyName": "Naquotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10584,
                    "pubMedId": 28954786,
                    "title": "A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28954786"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6045,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vizimpro (dacomitinib) and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification, EGFRvIII, and PTEN R308C in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 22287,
                "profileName": "EGFR act mut EGFR amp PTEN R308C"
            },
            "therapy": {
                "id": 4009,
                "therapyName": "BMS-754807 + Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6037,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification, EGFRvIII, and PTEN R308C in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 22287,
                "profileName": "EGFR act mut EGFR amp PTEN R308C"
            },
            "therapy": {
                "id": 4008,
                "therapyName": "Gefitinib + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6046,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vizimpro (dacomitinib) and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR (A289T, EGFRvIII) and PTEN (N69D, I253N) mutations in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 22288,
                "profileName": "EGFR A289T EGFR act mut PTEN N69D PTEN I253N"
            },
            "therapy": {
                "id": 4009,
                "therapyName": "BMS-754807 + Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6038,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring mutations in EGFR (EGFRvIII, A289T) and PTEN (I253N, N69D) in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 22288,
                "profileName": "EGFR A289T EGFR act mut PTEN N69D PTEN I253N"
            },
            "therapy": {
                "id": 4008,
                "therapyName": "Gefitinib + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6052,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) combination treatment did not improve growth inhibition compared to single therapy in InsR- and IGF1R-negative glioblastoma cell lines harboring EGFR amplification and EGFRvIII in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 22292,
                "profileName": "EGFR act mut EGFR amp IGF1R neg INSR neg"
            },
            "therapy": {
                "id": 4008,
                "therapyName": "Gefitinib + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6053,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vizimpro (dacomitinib) and BMS-754807 combination treatment did not improve growth inhibition compared to single therapy in InsR- and IGF1R-negative glioblastoma cell lines harboring EGFR amplification and EGFRvIII in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 22292,
                "profileName": "EGFR act mut EGFR amp IGF1R neg INSR neg"
            },
            "therapy": {
                "id": 4009,
                "therapyName": "BMS-754807 + Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6051,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, InsR- and IGF1R-negative glioblastoma cell lines harboring EGFR amplification and EGFRvIII were resistant to BMS-754807-induced growth inhibition in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 22292,
                "profileName": "EGFR act mut EGFR amp IGF1R neg INSR neg"
            },
            "therapy": {
                "id": 686,
                "therapyName": "BMS-754807",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6048,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) inhibited survival of InsR- and IGF1R-negative glioblastoma cell lines harboring EGFR amplification and EGFRvIII in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 22292,
                "profileName": "EGFR act mut EGFR amp IGF1R neg INSR neg"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6050,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, InsR- and IGF1R-negative glioblastoma cell lines harboring EGFR amplification and EGFRvIII were resistant to Linsitinib (OSI-906)-induced growth inhibition in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 22292,
                "profileName": "EGFR act mut EGFR amp IGF1R neg INSR neg"
            },
            "therapy": {
                "id": 798,
                "therapyName": "Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6049,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vizimpro (dacomitinib) inhibited survival of InsR- and IGF1R-negative glioblastoma cell lines harboring EGFR amplification and EGFRvIII in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 22292,
                "profileName": "EGFR act mut EGFR amp IGF1R neg INSR neg"
            },
            "therapy": {
                "id": 714,
                "therapyName": "Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6981,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABT-414 induced cytoxicity in a glioblastoma cell line harboring amplified EGFR vIII (exon 2-7 deletion) in culture, and induced complete tumor regression in cell line xenograft models of glioblastoma harboring amplified EGFR vIII (PMID: 26846818).",
            "molecularProfile": {
                "id": 24170,
                "profileName": "EGFR act mut EGFR amp"
            },
            "therapy": {
                "id": 976,
                "therapyName": "Depatuxizumab mafodotin",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5960,
                    "pubMedId": 26846818,
                    "title": "ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26846818"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6994,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABT-414 in combination with Temodar (temozolomide) and radiotherapy inhibited tumor growth and resulted in tumor growth delay in a glioblastoma multiforme cell line xenograft model harboring amplified EGFR vIII (exon 2-7 deletion), with increased efficacy compared to the combination of Temodar (temozolomide) and radiotherapy (PMID: 26846818).",
            "molecularProfile": {
                "id": 24170,
                "profileName": "EGFR act mut EGFR amp"
            },
            "therapy": {
                "id": 4346,
                "therapyName": "Depatuxizumab mafodotin + Radiotherapy + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5960,
                    "pubMedId": 26846818,
                    "title": "ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26846818"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6991,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABT-414 induced tumor regression in a patient-derived xenograft model of glioblastoma multiforme harboring amplified wild-type EGFR and EGFR vIII (exon 2-7 deletion) (PMID: 26846818).",
            "molecularProfile": {
                "id": 24172,
                "profileName": "EGFR act mut EGFR amp EGFR wild-type"
            },
            "therapy": {
                "id": 976,
                "therapyName": "Depatuxizumab mafodotin",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5960,
                    "pubMedId": 26846818,
                    "title": "ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26846818"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12372,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SYM015 treatment resulted in tumor growth inhibition in patient-derived xenograft (PDX) models of MET-amplified lung cancer harboring EGFR activating mutations (PMID: 28679766).",
            "molecularProfile": {
                "id": 28681,
                "profileName": "EGFR act mut MET amp"
            },
            "therapy": {
                "id": 4322,
                "therapyName": "SYM015",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10340,
                    "pubMedId": 28679766,
                    "title": "Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28679766"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12679,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, three non-small cell lung carcinoma patients initially harboring EGFR T790M and/or an EGFR activating mutation demonstrated a partial response to ASP8273 treatment, but later progressed, demonstrating in cell-free DNA, a reemergence of EGFR T790M and/or the EGFR activating mutation and EGFR C797S (PMID: 28954786; NCT02113813).",
            "molecularProfile": {
                "id": 28798,
                "profileName": "EGFR C797S EGFR act mut"
            },
            "therapy": {
                "id": 1082,
                "therapyName": "Naquotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10584,
                    "pubMedId": 28954786,
                    "title": "A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28954786"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12637,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of EGFR C797S in addition to other EGFR activating mutations including L858R, T790M, and exon 19 deletion (L747_P753delinsS) conferred resistance to Nazartinib (EGF816) in transformed cells in culture (PMID: 29285266).",
            "molecularProfile": {
                "id": 28798,
                "profileName": "EGFR C797S EGFR act mut"
            },
            "therapy": {
                "id": 1309,
                "therapyName": "Nazartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10505,
                    "pubMedId": 29285266,
                    "title": "Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29285266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12640,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of EGFR C797S in addition to other EGFR activating mutations including L858R, T790M, and exon 19 deletion (L747_P753delinsS) conferred resistance to Tarceva (erlotinib) in transformed cells in culture (PMID: 29285266).",
            "molecularProfile": {
                "id": 28798,
                "profileName": "EGFR C797S EGFR act mut"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10505,
                    "pubMedId": 29285266,
                    "title": "Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29285266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12638,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of EGFR C797S in addition to other EGFR activating mutations including L858R, T790M, and exon 19 deletion (L747_P753delinsS) conferred resistance to Tagrisso (osimertinib) in transformed cells in culture (PMID: 29285266).",
            "molecularProfile": {
                "id": 28798,
                "profileName": "EGFR C797S EGFR act mut"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10505,
                    "pubMedId": 29285266,
                    "title": "Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29285266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12639,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of EGFR C797S in addition to other EGFR activating mutations including L858R, T790M, and exon 19 deletion (L747_P753delinsS) conferred resistance to Gilotrif (afatinib) in transformed cells in culture (PMID: 29285266).",
            "molecularProfile": {
                "id": 28798,
                "profileName": "EGFR C797S EGFR act mut"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10505,
                    "pubMedId": 29285266,
                    "title": "Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29285266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12680,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, three non-small cell lung carcinoma patients initially harboring EGFR T790M and/or an EGFR activating mutation demonstrated a partial response to ASP8273 treatment, but later progressed, demonstrating in cell-free DNA, a reemergence of EGFR T790M and/or the EGFR activating mutation and EGFR C797S (PMID: 28954786; NCT02113813).",
            "molecularProfile": {
                "id": 28833,
                "profileName": "EGFR T790M EGFR C797S EGFR act mut"
            },
            "therapy": {
                "id": 1082,
                "therapyName": "Naquotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10584,
                    "pubMedId": 28954786,
                    "title": "A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28954786"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15806,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase I and a Phase II trial, MET amplification was identified at disease progression in 26% (11/43) of patients with non-small cell lung cancer harboring both EGFR T790M and another EGFR activating mutation (exon 19 deletion, 70%; L858R, 28%) treated with Rociletinib (CO-1686), conversely, preexisting MET, ERBB2 (HER2), or EGFR amplification were more common in patients with primary resistance to Rociletinib (CO-1686) (PMID: 27283993; NCT01526928, NCT02147990).",
            "molecularProfile": {
                "id": 31227,
                "profileName": "EGFR T790M EGFR act mut MET amp"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7047,
                    "pubMedId": 27283993,
                    "title": "Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27283993"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15811,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase I and a Phase II trial, ERBB2 (HER2) amplification was identified at disease progression in 9% (4/43) of patients with non-small cell lung cancer harboring both EGFR T790M and another EGFR activating mutation (exon 19 deletion, 70%; L858R, 28%) treated with Rociletinib (CO-1686), conversely, preexisting MET, ERBB2 (HER2), or EGFR amplification were more common in patients with primary resistance to Rociletinib (CO-1686) (PMID: 27283993; NCT01526928, NCT02147990).",
            "molecularProfile": {
                "id": 31239,
                "profileName": "EGFR T790M EGFR act mut ERBB2 amp"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7047,
                    "pubMedId": 27283993,
                    "title": "Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27283993"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15821,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase I and a Phase II trial, EGFR amplification was identified at disease progression in 9% (4/43) of patients with non-small cell lung cancer harboring both EGFR T790M and another EGFR activating mutation (exon 19 deletion, 70%; L858R, 28%) treated with Rociletinib (CO-1686), conversely, preexisting MET, ERBB2 (HER2), or EGFR amplification were more common in patients with primary resistance to Rociletinib (CO-1686) (PMID: 27283993; NCT01526928, NCT02147990).",
            "molecularProfile": {
                "id": 31243,
                "profileName": "EGFR T790M EGFR act mut EGFR amp"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7047,
                    "pubMedId": 27283993,
                    "title": "Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27283993"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15822,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase I and a Phase II trial, PIK3CA activating mutations were identified at disease progression in 12% (5/43) of patients with non-small cell lung cancer harboring both EGFR T790M and another EGFR activating mutation (exon 19 deletion, n=3; L858R, n=2) treated with Rociletinib (CO-1686), PIK3CA E542K was identified in 3 of the 5 patients (PMID: 27283993; NCT01526928, NCT02147990).",
            "molecularProfile": {
                "id": 31244,
                "profileName": "EGFR T790M EGFR act mut PIK3CA E542K"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7047,
                    "pubMedId": 27283993,
                    "title": "Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27283993"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15823,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase I and a Phase II trial, PIK3CA activating mutations were identified at disease progression in 12% (5/43) of patients with non-small cell lung cancer harboring both EGFR T790M and another EGFR activating mutation (exon 19 deletion, n=3; L858R, n=2) treated with Rociletinib (CO-1686), PIK3CA E545K was identified in 4 of the 5 patients (PMID: 27283993; NCT01526928, NCT02147990).",
            "molecularProfile": {
                "id": 31245,
                "profileName": "EGFR T790M EGFR act mut PIK3CA E545K"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7047,
                    "pubMedId": 27283993,
                    "title": "Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27283993"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15962,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, patients with EGFR mutant lung adenocarcinoma harboring an acquired EGFR T790M mutation and expressing high levels of nuclear Yap1 protein prior to treatment with EGFR tyrosine kinase inhibitors (n=4) had significantly shorter overall survival (p<0.001) than patients in a corresponding group with low nuclear Yap1 expressing (n=9), but no difference in progression-free survival (p=0.221) (PMID: 29487002).",
            "molecularProfile": {
                "id": 31342,
                "profileName": "EGFR T790M EGFR act mut YAP1 over exp"
            },
            "therapy": {
                "id": 6870,
                "therapyName": "unspecified EGFR tyrosine kinase inhibitor",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14077,
                    "pubMedId": 29487002,
                    "title": "Overexpression of YAP1 in EGFR mutant lung adenocarcinoma prior to tyrosine kinase inhibitor therapy is associated with poor survival.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29487002"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15961,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, patients with EGFR mutant lung adenocarcinoma expressing high levels of nuclear Yap1 protein (n=15) prior to treatment with EGFR tyrosine kinase inhibitors had decreased progression-free survival (9.8 vs 14.2 months) and overall survival (21.1 vs 36.3 months) compared to patients with low nuclear Yap1 expression (PMID: 29487002).",
            "molecularProfile": {
                "id": 31343,
                "profileName": "EGFR act mut YAP1 over exp"
            },
            "therapy": {
                "id": 6870,
                "therapyName": "unspecified EGFR tyrosine kinase inhibitor",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14077,
                    "pubMedId": 29487002,
                    "title": "Overexpression of YAP1 in EGFR mutant lung adenocarcinoma prior to tyrosine kinase inhibitor therapy is associated with poor survival.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29487002"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 423,
            "profileName": "EGFR act mut",
            "profileTreatmentApproaches": [
                {
                    "id": 3485,
                    "name": "EGFR Inhibitor 3rd gen",
                    "profileName": "EGFR act mut"
                },
                {
                    "id": 3484,
                    "name": "EGFR Inhibitor 2nd gen",
                    "profileName": "EGFR act mut"
                },
                {
                    "id": 3482,
                    "name": "EGFR Inhibitor (Pan)",
                    "profileName": "EGFR act mut"
                },
                {
                    "id": 4595,
                    "name": "HER inhibitor (Pan)",
                    "profileName": "EGFR act mut"
                },
                {
                    "id": 3483,
                    "name": "EGFR Inhibitor 1st gen",
                    "profileName": "EGFR act mut"
                }
            ]
        },
        {
            "id": 3199,
            "profileName": "EGFR act mut HGF over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 13014,
            "profileName": "EGFR T790M EGFR act mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22287,
            "profileName": "EGFR act mut EGFR amp PTEN R308C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22288,
            "profileName": "EGFR A289T EGFR act mut PTEN N69D PTEN I253N",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22292,
            "profileName": "EGFR act mut EGFR amp IGF1R neg INSR neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24170,
            "profileName": "EGFR act mut EGFR amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24172,
            "profileName": "EGFR act mut EGFR amp EGFR wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26975,
            "profileName": "EGFR act mut SDCBP pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28681,
            "profileName": "EGFR act mut MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28798,
            "profileName": "EGFR C797S EGFR act mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28833,
            "profileName": "EGFR T790M EGFR C797S EGFR act mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31227,
            "profileName": "EGFR T790M EGFR act mut MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31239,
            "profileName": "EGFR T790M EGFR act mut ERBB2 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31243,
            "profileName": "EGFR T790M EGFR act mut EGFR amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31244,
            "profileName": "EGFR T790M EGFR act mut PIK3CA E542K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31245,
            "profileName": "EGFR T790M EGFR act mut PIK3CA E545K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31342,
            "profileName": "EGFR T790M EGFR act mut YAP1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31343,
            "profileName": "EGFR act mut YAP1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}